New Merck and Vertex drugs raise standard of care in hepatitis C

@article{Sheridan2011NewMA,
  title={New Merck and Vertex drugs raise standard of care in hepatitis C},
  author={Cormac Sheridan},
  journal={Nature Biotechnology},
  year={2011},
  volume={29},
  pages={553-554}
}
for people on Victrelis-based triple therapy. But the newly approved drugs also have major shortcomings, adding an extra safety and toxicity burden to a treatment that is already difficult to take. Victrelis requires a complicated dosing regimen and also increases the risk of anemia and of neutropenia that can be of lifethreatening severity. Treatment with Vertex’s Incivek, though shorter than its competitor’s, is associated with increased incidence of severe rash, anemia and pruritus. Merck… CONTINUE READING
14 Extracted Citations
0 Extracted References
Similar Papers

Citing Papers

Publications influenced by this paper.
Showing 1-10 of 14 extracted citations

Similar Papers

Loading similar papers…